Canasa (Mesalamine) Patent Expiration, LOE Window & CMS Spending
Canasa (Mesalamine) by AbbVie: FDA Orange Book LOE 2028-06-06, 8 AB generics, $2.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N021252 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-06-06 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $2.5M |
| 2024 Medicare Part D Spend | $1.2M |
| 2024 Medicaid Spend | $1.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.